 NEW YORK, May 14, 2021 PRNewswire -- Lyfebulb, a patient-empowerment innovation accelerator that bridges the gap between patient communities and the healthcare industry, and CSL Behring, a global biotherapeutics leader driven by its promise to save and improve lives, are excited to announce that Dr. Minnie Sarwal of NephroSant was selected as the winner of the Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation. Dr. Minnie Sarwal of NephroSant wins the 2021 Lyfebulb CSL Behring Innovation Challenge in Transplantation NephroSant will receive the 25,000 monetary award to further develop diagnostic tools for early detection and lifetime monitoring of kidney health and injury, including a non-invasive transplant rejection test designed specifically for kidneys. 